<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151495">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02048189</url>
  </required_header>
  <id_info>
    <org_study_id>RUDONI PARI 2011</org_study_id>
    <nct_id>NCT02048189</nct_id>
  </id_info>
  <brief_title>Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes</brief_title>
  <acronym>TRICIDIA</acronym>
  <official_title>Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open multicentre, randomized study to compare two treatment arms. One arm called
      &quot;intensification of multiple injections&quot; in which the patient will receive one supplementary
      injection of LEVEMIR®: that is to say 5 injections per day, and an arm called &quot;continuous
      insulin infusion&quot; via an external pump with APIDRA®.

      In the pump arm: a favorable effect in terms of improved insulin sensitivity, improved
      metabolic equilibrium, a decrease in the area under the baseline and prandial hyperglycemia
      curve noted during the continuous glycemia recording; an improvement in quality of life
      compared with treatment using multiple injections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Mixed measurement of insulin secretion and insulin resistance</measure>
    <time_frame>Change from baseline insulin secretion and insuline resistance at 6 month after starting the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in the time spent in baseline and prandial hyperglycemia</measure>
    <time_frame>During the 6 months following initiation of the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy</condition>
  <arm_group>
    <arm_group_label>Intensified multiple injections</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pumps</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEVEMIR</intervention_name>
    <arm_group_label>Intensified multiple injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APIDRA</intervention_name>
    <arm_group_label>Pumps</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons who have provided written informed consent

          -  Age &gt; 18 years

          -  Patients with type 2 diabetes treated with insulin using a basal / bolus strategy for
             at least 6 months

          -  Doses of insulin &gt; 0.7 U / Kg / d

          -  HbA1c ≥ 7.5 %

          -  Without OAD for at least 4 weeks (sulfamides, Incretines, glinides, acarbose) except
             Metformin

          -  BMI ≥ 28.5 kg / m2

          -  Diabetes diagnosed for at least 10 years

          -  Patients able to monitor themselves and manage an insulin pump.

        Exclusion Criteria:

          -  Patients treated with glitazones during the 3 months preceding inclusion

          -  Patients with proliferative ischemic retinopathy not treated by laser

          -  BMI &lt; 28.5 kg / m2

          -  Presence of implantable material ( CI MRI )

          -  Pacemaker ( CI MRI )

          -  Pregnancy, breast feeding

          -  Medically significant physical or psychiatric inability, patients under guardianship
             or wards of court

          -  The practice of violent sports

          -  Poor conditions of hygiene

          -  Professional environment of extreme cold or heat.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sabine BAILLOT-RUDONI</last_name>
    <phone>3.80.29.34.53</phone>
    <phone_ext>+33</phone_ext>
    <email>sabine.rudoni@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred PENFORMIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine BAILLOT-RUDONI</last_name>
      <phone>3.80.29.34.53</phone>
      <phone_ext>+33</phone_ext>
      <email>sabine.rudoni@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle SIMONEAU-ROBIN</last_name>
      <phone>3 80 29 33 32</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.simoneau-robin@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
